Biolase’s ezlase wins FDA clearance for pain therapy and relief

The FDA has given clearance to the ezlase for the following indications: for a temporary relief of minor muscle and joint pain and stiffness, minor arthritis pain, or muscle spasm, minor sprains and strains, and minor muscular back pain; the temporary increase in local blood circulation and the temporary relaxation of muscle.

In addition to dental applications, the new FDA clearance opens the door to market the system for a range of non-dental pain relief applications, including sports medicine, orthopedics, physical therapy and chiropractics. Biolase is in discussions to determine the best approach to market the laser system for these new applications.

The ezlase system is marketed, sold and serviced to dental professionals by the company’s exclusive North American distribution partner Henry Schein.

David Mulder, CEO of Biolase, said: This represents a significant increase in application of our diode technology and ultimately an opportunity to increase sales of our ezlase systems worldwide, strengthening our position in the diode laser market.

We now have the only dental diode laser system that is cleared for soft tissue procedures, teeth whitening and pain relief. This is yet another milestone towards our goal of increased patient satisfaction, improved outcomes and enhanced practice profitability, positioning our laser systems as the instruments of choice among practitioners and patients.